Literature DB >> 20562216

The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent.

Agnieszka Pałucha-Poniewiera1, Piotr Brański, Tomasz Lenda, Andrzej Pilc.   

Abstract

Behavioral studies show that modulation of the glutamatergic system might be an efficient way to achieve antidepressant activity. Among the group III metabotropic glutamate (mGlu) receptors, the mGlu7 receptor subtype seems to be the most promising target for potential antidepressants. It has been shown that a selective, allosteric mGlu7 receptor agonist, N,N'-bis (diphenylmethyl)-1,2-ethanediamine (AMN082), induced antidepressant-like action in behavioral tests in mice, although the mechanisms responsible for this action remained unknown. Here, we decided to investigate the possible role of the serotonergic system in the antidepressant-like activity of AMN082 in both the forced swim test (FST) in rats and the tail suspension test (TST) in mice. We found that AMN082 (1-10 mg/kg i.p.) induced a dose-dependent reduction in the immobility of rats and an increase in their swimming behavior, whereas there were not any changes in climbing behavior in the FST in rats. In the TST in mice we found that AMN082 (3 mg/kg i.p.) did not induce an antidepressant-like effect after depletion of serotonin (5-HT) with para-chlorophenylalanine. Moreover, we revealed that citalopram, but not reboxetine, when combined with AMN082 (all compounds used at low subeffective doses), induced a significant antidepressant-like effect in the TST. We also discovered that the 5-HT1A receptor antagonist N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-carboxamide (WAY100635) (0.1 mg/kg s.c.), but not the 5-HT2A/2C receptor antagonist ritanserin (0.5 mg/kg i.p.), blocked the antidepressant-like action of AMN082. Altogether, the results of our studies show that the antidepressant-like action of the mGlu7 receptor-positive modulator AMN082 depends on the activation of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562216     DOI: 10.1124/jpet.110.169730

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Authors:  C Ullmer; S Zoffmann; B Bohrmann; H Matile; L Lindemann; Pj Flor; P Malherbe
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.

Authors:  Agnieszka Pałucha-Poniewiera; Piotr Brański; Joanna M Wierońska; Katarzyna Stachowicz; Anna Sławińska; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

Review 3.  Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence.

Authors:  Xia Li; Athina Markou
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 4.  Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.

Authors:  Xia Li; Zheng-Xiong Xi; Athina Markou
Journal:  Neuropharmacology       Date:  2012-04-21       Impact factor: 5.250

5.  Novel Glutamatergic Treatments for Severe Mood Disorders.

Authors:  Minkyung Park; Mark J Niciu; Carlos A Zarate
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-09

Review 6.  Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants.

Authors:  Shigeyuki Chaki; Kenichi Fukumoto
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-17

Review 7.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

8.  The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Authors:  Joanna M Wierońska; Francine C Acher; Anna Sławińska; Piotr Gruca; Magdalena Lasoń-Tyburkiewicz; Mariusz Papp; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2013-03-10       Impact factor: 4.530

Review 9.  The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.

Authors:  Daniel Peterlik; Peter J Flor; Nicole Uschold-Schmidt
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.